



# Best Agrolife Limited

CIN : L74110DL1992PLC116773

13th November, 2025

To

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block-G,  
Bandra - Kurla Complex  
Bandra (E), Mumbai-400051

BSE Limited  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street, Mumbai-400001

SCRIP CODE: 539660

SCRIP ID: BESTAGRO

**Sub: Intimation under Regulation 30 Corporate Presentation**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended please find the attached Corporate Presentation.

Submitted for your information and record.

Thanking You,

Yours Faithfully,

For Best Agrolife Limited

*Aarti Arora*  
Aarti Arora  
CS & Compliance Officer



Encl. as above





**Best Agrolife Limited**

**Q2 FY25-26**





# Disclaimer



*The Presentation is to provide the general background information about the company's activities as at the date of the presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe or purchase the company shares. The company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.*

*This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global chemical and pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.*

*No part of this presentation may be reproduced, quoted or circulated without prior written approval from Best Agrolife Ltd.*







# Table of Contents



Company Snapshot



Management Comment



Business Highlights



Financial Highlights



Way Ahead







# Company Snapshot



**15<sup>th</sup>**

Largest Indian  
Agrochemical  
Company\*

**40**

Warehouses  
21 States

**9**

Patented  
Products

**10,000+**

Dealers

**4**

Manufacturing units  
7000 MTPA Technical  
35500 KL Formulation

**530+**

Formulations  
Registrations

**800+**

Employees

**14%**

3 Year Revenue  
CAGR

*\*Agropages Top 20 Indian Agrochemical Companies*



# Management Comment



**Mr. Vimal Kumar**

Managing Director

"In this Kharif season an **erratic monsoon** has once again shown the dependence of Indian agriculture on the **quantity** and **timing** of rains. The errant rains posed **several challenges**, with unexpected as well as extended **heavy rainfall** across key agricultural regions, which in turn **impacted** the overall demand pattern for agrochemicals. Despite these conditions, **Best Agrolife** has navigated the season through disciplined **operations management**, **dynamic inventory control**, and a **strong on-ground presence**. We continue to focus on **leaner inventories** and **financial discipline**.

The business is steadily progressing toward **stabilization**, with notable improvements in key operational areas including **lower sales returns**, and optimization of **operating expenses (OPEX)** as well as a tight **control on inventory**. Inventory levels have **decreased** by ₹207 crore, from ₹873 crore in H1 FY25 to ₹666 crore in H1 FY26, marking a **24% year-on-year** reduction. Through strategic restructuring across regional operations, the company has achieved an **OPEX reduction of 13%** compared to Q2 FY25 and **11%** compared to H1 FY25. We believe this belt tightening will be the base for our future.

Traditionally, the **agrochemical industry** experiences the **major sales returns** in the **third quarter**. However, driven by our **revised sales return policy** and **in-season** order placement strategy, we anticipate significantly **lower sales returns** in Q3 FY26.

Our **focus on patented products** is now contributing over **half** of our **brand portfolio**, enhancing **brand value**, **margin profile**, and **competitive advantage**. Despite moderation in the **overall revenue**, the **quality** of our revenue mix has **improved significantly**, reflecting our commitment to **sustainable** and **value-driven** long-term growth. **Restructuring the sales force** across the regional operations has improved the sales team **productivity** and led to reduction in the **operating expenses**."



# Patented Products



## RONFEN™ Insecticide (SC)

Pyriproxyfen - 8%  
Dinotefuran - 5%  
Diafenthiuron - 18%

Crops - Brinjal, Cotton  
Pests - Sucking Pests & Thrips

FY22-23



## TRICOLOR™ Fungicide (SC)

Trifloxystrobin - 10%  
Difenoconazole - 12.5%  
Sulfur - 3%

Crops - Tomato  
Fungus - Early & Late Blight

FY23-24



## ORISULAM™ Herbicide (GR)

Bispyribac Sodium - 0.25%  
Penoxsulam - 0.25%  
Pyrazosulfuron Ethyl - 0.20%

Crops - Transplanted Rice  
Weeds - Sedges, Grasses & Broad Leaves



## DEFENDER™ Insecticide + Fungicide (WG)

Pymetrozine - 30%  
Dinotefuran - 10%  
Pyraclostrobin - 20%

Crops - Paddy  
Pests/Fungus - BPH & Blast

FY24-25



## NEMAGEN™ Insecticide (SC)

Chlorantraniliprole - 4.5%  
Novaluron - 11.5%  
Emamectin Benzoate - 1.5%

Crops - Brinjal  
Pests - Borer



## WARDEN EXTRA™ Insecticide + Fungicide (FS)

Trifloxystrobin - 6%  
Thiamethoxam - 24%  
Thiophanate Methyl - 9.5%

Crops - Okra  
Pests - Aphids, Leaf Hopper & Whitefly

FY24-25



## SHOT DOWN™ Herbicide (ME)

Haloxyp-R Methyl - 12.8%  
Imazethapyr - 10%

Crops - Soyabean  
Weeds - Grasses & Sedges



## FETAGEN™ Insecticide (GR)

Chlorantraniliprole - 0.45%  
Fipronil - 0.5%  
Emamectin Benzoate - 0.18%

Crops - Tomato  
Pests - Whitefly & Fruit Borer

FY25-26



## BEST MAN™ Insecticide (SC)

Fipronil - 7%  
Abamectin - 1.25%  
Tolfenpyrad - 15%

Crops - Chilli  
Pests - Aphids, Jassids, Thrips, Whitefly, Mites, Borer

# Business Highlights

- Q2 FY26 revenue stood at ₹516.8 crore, compared to ₹746.6 crore in Q2 FY25, reflecting a 30.8% YoY decline. The reduction was due to combination of erratic rainfall and lower placements.
- The Company's ongoing efforts to stabilize operations and rationalize inventory have delivered strong results, with inventory levels reduced by ₹207 crore, from ₹873 crore in H1 FY25 to ₹666 crore in H1 FY26, representing a 24% reduction YoY.
- H1 FY26 revenue was ₹898.1 crore, compared to ₹1,265.9 crore in H1 FY25.
- Gross Margin for Q2 FY26 was ₹169.6 crores, in line with reduced topline but supported by improved mix in patented products.
- With strategic restructuring across regional operations the company has achieved OPEX reduction of 13% in comparison to Q2 FY25 and 11% in comparison to H1 FY25.
- EBITDA Margin stood at 15.0% in Q2 FY26, compared to 19.7% last year, primarily due to lower sales volume, and was partially offset by cost controls.
- H1 FY26 EBITDA Margin remained stable at 13.7%, demonstrating early benefits of efficiency measures.
- PAT for Q2 FY26 was ₹38.9 crore, compared to ₹94.7 crore in Q2 FY25.
- The share of patented products increased from 38% in Q2 FY25 to 51% in Q2 FY26, reflecting a strategic shift toward innovation, proprietary formulations, and higher-margin offerings.
- The brand segment contributed 68% and the institutional segment 32% of total revenue in FY25-26, with the former maintaining its strong share despite a softer topline and the latter showing a marginal improvement in mix share.
- Received 4 9(3) FIM Registrations and 4 Patents for innovations.









# Financial Highlights


## Revenue From Operations



## EBITDA\*



## PAT



## EPS



\*EBITDA is calculated excluding other income








# Building a Branded Business



Branded v/s Institutional Sales



Contribution of Patented products in Branded Sales



Best Man™



Fetagen™



Shot Down™



Nemagen™



Defender™



Orrisulam™



Warden Extra™



Tricolor™



Ronfen™





# Consolidated P&L for Q2 FY26



| Value (INR Cr)          | Q2 FY26 | Q2 FY25 | YoY      | H1 FY26 | H1 FY25 |
|-------------------------|---------|---------|----------|---------|---------|
| Revenue from Operations | 516.8   | 746.6   | -30.8%   | 898.1   | 1265.9  |
| Gross Margin            | 169.6   | 252.1   | -32.7%   | 280.2   | 379.4   |
| EBITDA*                 | 77.5    | 147.1   | -47%     | 123.3   | 201.7   |
| EBITDA Margin (%)       | 15%     | 19.7%   | -470 Bps | 13.7%   | 16%     |
| Profit After Tax        | 38.9    | 94.7    | -58.9%   | 58.9    | 115.9   |
| PAT Margin (%)          | 7.56%   | 12.66%  | -510 Bps | 6.5%    | 9%      |

\*EBITDA is calculated excluding other income



# Consolidated P&L for Q2 FY26



| Value (INR Cr)                | Q2 FY26 | Q2 FY25 | YoY      | Q1 FY26 |
|-------------------------------|---------|---------|----------|---------|
| Revenue from Operations       | 516.8   | 746.6   | -30.8%   | 381     |
| Other Income                  | -2      | 1       |          | 4       |
| Total Revenue                 | 515     | 748     | -31%     | 385     |
| Cost of Goods Sold            | 347     | 495     |          | 271     |
| Employee Benefits Expense     | 24      | 29      |          | 25      |
| Other Operating Expenses      | 68      | 76      |          | 39      |
| Total Expenses                | 439     | 600     |          | 335     |
| EBITDA*                       | 77.5    | 147.1   |          | 46      |
| EBITDA Margin (%)             | 15%     | 20%     | -470 Bps | 12%     |
| Depreciation and Amortisation | 10      | 10      |          | 10      |
| Finance Cost                  | 13      | 16      |          | 14      |
| Profit Before Tax             | 52      | 121     | -57%     | 26      |
| PBT Margin (%)                | 10%     | 16%     | -603 Bps | 7%      |
| Profit After Tax              | 38.9    | 94.7    | -58.9%   | 20      |
| PAT Margin (%)                | 7.56%   | 12.66%  | -510 Bps | 5%      |

\*EBITDA is calculated excluding other income





# Consolidated P&L for H1 FY26



| Value (INR Cr)                | H1 FY26 | H1 FY25 | FY25  |
|-------------------------------|---------|---------|-------|
| Revenue from Operations       | 898     | 1266    | 1814  |
| Other Income                  | 2       | 4       | 5     |
| Total Revenue                 | 900     | 1270    | 1819  |
| Cost of Goods Sold            | 618     | 886     | 1283  |
| Employee Benefits Expense     | 49      | 55      | 107   |
| Other Operating Expenses      | 108     | 123     | 224   |
| Total Expenses                | 775     | 1064    | 1614  |
| EBITDA*                       | 123     | 202     | 200   |
| EBITDA Margin (%)             | 14%     | 16%     | 11%   |
| Depreciation and Amortisation | 21      | 20      | 43    |
| Finance Cost                  | 27      | 32      | 66    |
| Profit Before Tax             | 78      | 153     | 96    |
| PBT Margin (%)                | 9%      | 12%     | 5%    |
| Profit After Tax              | 58.9    | 116     | 33    |
| PAT Margin (%)                | 7%      | 9%      | 2%    |
| Diluted EPS                   | 24.89   | 49.03   | 29.56 |

\*EBITDA is calculated excluding other income



# Consolidated Balance sheet




| Value (INR Cr)                       | As on Sept 30, 2025 | As on Sept 30, 2024 | As on Mar 31, 2025 |
|--------------------------------------|---------------------|---------------------|--------------------|
| <b>Equity And Liabilities</b>        |                     |                     |                    |
| Share Holders Fund                   | 809                 | 756                 | 758                |
| Non-current Liabilities              |                     |                     |                    |
| • Long Term Borrowings               | 12                  | 18                  | 14                 |
| • Other Financial Liabilities        | 33                  | 36                  | 41                 |
| <b>Total Non-current Liabilities</b> | <b>45</b>           | <b>54</b>           | <b>55</b>          |
| <b>Current Liabilities</b>           |                     |                     |                    |
| • Short Term Borrowings              | 413                 | 552                 | 453                |
| • Trade Payable                      | 554                 | 919                 | 542                |
| • Other Current Liabilities          | 142                 | 122                 | 142                |
| <b>Total Current Liabilities</b>     | <b>1,109</b>        | <b>1,593</b>        | <b>1,137</b>       |
| <b>Total Equity &amp; Liability</b>  | <b>1963</b>         | <b>2,403</b>        | <b>1,950</b>       |
| <b>Assets</b>                        |                     |                     |                    |
| Non-current Assets                   |                     |                     |                    |
| • Net Fixed Asset                    | 164                 | 163                 | 177                |
| • Intangible Asset                   | 127                 | 135                 | 131                |
| • Other Non Current Assets           | 87                  | 102                 | 90                 |
| <b>Total Non-current Assets</b>      | <b>378</b>          | <b>400</b>          | <b>398</b>         |
| <b>Current Assets</b>                |                     |                     |                    |
| • Inventories                        | 666                 | 873                 | 773                |
| • Trade Receivables                  | 783                 | 958                 | 564                |
| • Cash & Bank Balance                | 69                  | 119                 | 99                 |
| • Other Current Assets               | 67                  | 53                  | 116                |
| <b>Total Current Assets</b>          | <b>1,585</b>        | <b>2,003</b>        | <b>1,552</b>       |
| <b>Total Assets</b>                  | <b>1,963</b>        | <b>2,403</b>        | <b>1,950</b>       |




# Key Ratios




### Debt to Equity (x)




### Net Debt to Equity (x)



### Current Ratio (x)



### ROCE



\*Formulae:


ROCE= EBIT/ Capital Employed\*100 (Capital Employed = Total Assets – current liabilities + Short term borrowings)

Debt to Equity = Total Debt / Shareholders fund; Net Debt to Equity = Total Debt - Cash & Bank Balances / Shareholders fund

Current ratio = Current Assets / Current liabilities



# Working Capital Movement







# Inventory and AR



Inventory



Accounts Receivables





# Experienced Management Team



**Mr. Vimal Alawadhi**

Managing Director

A true visionary and a passionate entrepreneur, Mr Vimal Alawadhi is an eminent personality with vast and rich experience in the Agrochemicals Industry. He oversees strategy, management, development, and integration of the company policies. With Best Agrolife he is pioneering endeavors to provide farmers with safe agrochemical products at economical prices.

He has been Interviewed by international magazines from "African Farming and Food Processing" to the publication Agro Pages, where he spoke on the "Taking Indian Brands and Leaders, Strides towards Make in India". In the 2018 edition of India Suppliers Guide, Mr. Vimal's views were published as "An Agrochemical Perspective from India". In 2019, he was featured in the Forbes India magazine's & in 2022 featured in Fortune India magazine.



**Mr. P. N. Karlekar**

Director

A chemical Engineer from UDCT- one of the top Indian Institute for Chemical Technology and a Management Graduate from Mumbai University, he has a diverse and rich professional background.

He has been associated at the apex level with reputed organizations such as -Rallis India Ltd as President Technology, thereafter worked at leadership levels including as President of the Agrochemical division of Atul Ltd, as COO of Deepak Nitrite Ltd., as Managing Director of Cheminova India Ltd from 2008 and subsequently as its President international region comprising of Asia-Pacific, Africa, Middle East. Later on, post-global acquisition of Cheminova by FMC corp (USA), he assumed the position of country head for FMC India. In these assignments he worked on strategic areas such as mergers and acquisitions and global business development etc.



**Mr. N Surendra Sai**

Director

A passionate technologist and entrepreneur having 31 years of extensive experience and understanding of Organizational Program Management, Business Analytics, Innovation, Startup Culture and Technology. He has held various leadership positions at private and government sectors with national and international exposure. In his 15 years stint at Wipro Technologies, held the roles of Delivery Head (PES), Program Head of Microsoft Windows Sustainance Engineering Services, Head of Cost of Delivery Optimization.

As a scientist with DRDO he worked on technology development and R&D for critical systems of national importance. He was instrumental in creating India's first Quantum Secure Communication Stack for National Agencies.

In his earlier stint with Best Group, The R&D environment created by him established a foundation for manufacturing of next generation molecules.



**Mr. Vikas Jain**

Chief Financial Officer

A seasoned finance professional with over two decades of experience in Accounts, Finance, Treasury, Taxation, Budgeting, MIS, Auditing, IT, and Legal. With a distinguished career including roles at ADAMA India Pvt Ltd, KPMG, and Price Waterhouse, Mr. Jain's leadership has been recognized with the 'CFO 100 Roll of Honour' Award in both 2020 and 2022. Armed with an Executive MBA (PGPMAX 2022) from the Indian School of Business (ISB) and certification in International Financial Reporting Standards (IFRS) from ACCA, UK, Mr. Jain has a profound understanding of the agrochemical industry and global financial practices.





# Thank You

Contact Us:  
[ir@bestagrolife.com](mailto:ir@bestagrolife.com)  
(Investor Relations)

## DISCLAIMER

This presentation includes certain forward looking statements and information including statements concerning the outlook for business. The statements are based on certain expectations, assumptions, anticipated developments and other factors which are not limited to, risks, uncertainties and assumptions based on current expectations, within the meaning of applicable laws and regulations. Forward-looking statements are based on current expectations, estimates and projections about the factors that may affect our future performance, including global economic conditions. The expectations, estimations and projections are majorly identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects" and similar expressions. There are numerous risk and uncertainties, way beyond our control, that could cause our actual results to differ from the forward looking information and statements made in this presentation. The company, based on changes stated above, may alter, amend, modify or make necessary changes in any manner to any such forward looking statement contained herein or make, written or oral forward looking statement as may be required from time to time basis of subsequent developments and events. No part of this presentation may be reproduced, quoted or circulated without the prior approval from Best Agrolife Ltd.

